IMPRiND Project

Latest news

Erwan Bézard awarded one of the prestigious @ERC_Research Synergy Grants.

The laboratories of Erwan Bézard (Research Director INSERM; Institute of Neurodegenerative Disorders), Laurent Groc (Research Director CNRS ...

It’s #CRISPR.

Emmanuelle Charpentier and Jennifer Doudna ,who pioneered the revolutionary gene-editing technology, are the winners of this year’s ...

Joined publication in JNC by IMPRiND partners BRFAA and CNRS.

The collaboration within IMPRiND lead to a publication on Journal of Neurochemistry untitled " Distinct alpha‐Synuclein species induced ...

Blocking aggregate propagation in neurodegenerative diseases


Blocking aggregate propagation in neurodegenerative diseases IMPRiND – Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases – is an international consortium that aims to map and target critical steps in the propagation of misfolded tau and α-synuclein, considered the main culprits of neurodegeneration in Alzheimer's and Parkinson's disease respectively. Our plans are built upon:
  • Identify disease-relevant misfolded assemblies, imprint their biological properties in vitro and/or in cellulo and generate homogeneous populations in order to assay and interfere with their pathogenic effects.
  • Develop and miniaturise assays to monitor up-take, secretion, clearance and oligomerisation using bimolecular fluorescence complementation of oligomeric species or transfer of untagged assemblies to fluorescently labelled fibril-naïve cells and measure markers of early proteotoxicity that are suitable for high throughput or high content screens.
  • Perform genetic screens based on disease-relevant gene/protein networks and assess druggability of identified targets.
  • Deliver robust validation assays for these molecular events in complex cellular systems with greater functional resemblance to the native milieu of the brain such as iPSC-based models and organotypic cultures or simple model organisms such as Drosophila or zebrafish.
  • Improve existing animal models in order to standardise pathological readouts for in vivo validation of modifiers, correlate them with novel peripheral or in situ markers using microdialysis to accelerate the assessment of therapeutic interventions and relevance to humans, e.g. by transplantation of human iPSC neurons in animals.
In the IMPRiND consortium, we will construct this entire pipeline to examine the propagation of α-synuclein and tau and test their tractability against disease progression.
IMPRIND started in March 2017 and will run until February 2021.

Most recent publications

1.
Distinct alpha‐Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH‐SY5Y cells.
Journal of Neurochemistry jnc.15174 (2020). doi:10.1111/jnc.15174
2.
Prominent microglial inclusions in transgenic mouse models of α-synucleinopathy that are distinct from neuronal lesions.
Acta Neuropathologica Communications 8, 133 (2020). doi:10.1186/s40478-020-00993-8
3.
The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies.
Acta Neuropathologica 139, 977–1000 (2020). doi:10.1007/s00401-020-02157-3
4.
Structures of α-synuclein filaments from multiple system atrophy.
Nature 1–6 (2020). doi:10.1038/s41586-020-2317-6
5.
Emergence of stealth polymorphs that escape α-synuclein amyloid monitoring, take over and acutely spread in neurons.
(Neuroscience, 2020). http://biorxiv.org/lookup/doi/10.1101/2020.02.11.943670.
6.
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
bioRxiv 2020.01.27.921643 (2020). doi:10.1101/2020.01.27.921643
7.
Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs.
Biophysical Journal (2020). doi:10.1016/j.bpj.2020.01.022
8.
The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding.
Scientific Reports 10, 4895 (2020). doi:10.1038/s41598-020-61757-x
9.
α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb.
Acta Neuropathologica Communications 7, 221 (2019). doi:10.1186/s40478-019-0859-3
10.
Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy.
eLife 8, e48907 (2019). doi:10.7554/eLife.48907
11.
Novel tau filament fold in corticobasal degeneration, a four-repeat tauopathy.
bioRxiv 811703 (2019). doi:10.1101/811703
12.
Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
Neurobiology of Disease 129, 38–43 (2019). doi:10.1016/j.nbd.2019.05.002
13.
The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.
Frontiers in Immunology 10, 1139 (2019). doi:10.3389/fimmu.2019.01139
14.
Pharmacological Transdifferentiation of Human Nasal Olfactory Stem Cells into Dopaminergic Neurons.
Stem Cells International 2019, 1–15 (2019). doi:10.1155/2019/2945435
15.
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved.
Frontiers in Molecular Neuroscience 12, 107 (2019). doi:10.3389/fnmol.2019.00107
16.
Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-02014-y
17.
Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules.
Nature 568, 420–423 (2019). doi:10.1038/s41586-019-1026-5
18.
LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-01995-0
19.
Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network.
Stem Cell Reports (2019). doi:10.1016/j.stemcr.2018.12.007
20.
Clustering of Tau fibrils impairs the synaptic composition of α3‐Na+/K+‐ATPase and AMPA receptors.
The EMBO Journal e99871 (2019). doi:10.15252/embj.201899871
21.
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
Journal of Neurochemistry 150, 522–534 (2019). doi:10.1111/jnc.14808
22.
How is alpha‐synuclein cleared from the cell?.
Journal of Neurochemistry 150, 577–590 (2019). doi:10.1111/jnc.14704
23.
Structures of filaments from Pick’s disease reveal a novel tau protein fold.
Nature 561, 137–140 (2018). doi:10.1038/s41586-018-0454-y
24.
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson’s disease cohort versus Parkinson’s disease: 123I-FP-CIT IMAGING IN A P.A53T PD COHORT.
Movement Disorders 33, 1734–1739 (2018). doi:10.1002/mds.27451
25.
Cryo-EM structures of tau filaments from Alzheimer’s disease.
Nature 547, 185–190 (2017). doi:10.1038/nature23002

1.
Distinct alpha‐Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH‐SY5Y cells.
Journal of Neurochemistry jnc.15174 (2020). doi:10.1111/jnc.15174
2.
Prominent microglial inclusions in transgenic mouse models of α-synucleinopathy that are distinct from neuronal lesions.
Acta Neuropathologica Communications 8, 133 (2020). doi:10.1186/s40478-020-00993-8
3.
The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies.
Acta Neuropathologica 139, 977–1000 (2020). doi:10.1007/s00401-020-02157-3
4.
Structures of α-synuclein filaments from multiple system atrophy.
Nature 1–6 (2020). doi:10.1038/s41586-020-2317-6
5.
Emergence of stealth polymorphs that escape α-synuclein amyloid monitoring, take over and acutely spread in neurons.
(Neuroscience, 2020). http://biorxiv.org/lookup/doi/10.1101/2020.02.11.943670.
6.
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
bioRxiv 2020.01.27.921643 (2020). doi:10.1101/2020.01.27.921643
7.
Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs.
Biophysical Journal (2020). doi:10.1016/j.bpj.2020.01.022
8.
The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding.
Scientific Reports 10, 4895 (2020). doi:10.1038/s41598-020-61757-x
9.
α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb.
Acta Neuropathologica Communications 7, 221 (2019). doi:10.1186/s40478-019-0859-3
10.
Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy.
eLife 8, e48907 (2019). doi:10.7554/eLife.48907
11.
Novel tau filament fold in corticobasal degeneration, a four-repeat tauopathy.
bioRxiv 811703 (2019). doi:10.1101/811703
12.
Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
Neurobiology of Disease 129, 38–43 (2019). doi:10.1016/j.nbd.2019.05.002
13.
The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.
Frontiers in Immunology 10, 1139 (2019). doi:10.3389/fimmu.2019.01139
14.
Pharmacological Transdifferentiation of Human Nasal Olfactory Stem Cells into Dopaminergic Neurons.
Stem Cells International 2019, 1–15 (2019). doi:10.1155/2019/2945435
15.
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved.
Frontiers in Molecular Neuroscience 12, 107 (2019). doi:10.3389/fnmol.2019.00107
16.
Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-02014-y
17.
Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules.
Nature 568, 420–423 (2019). doi:10.1038/s41586-019-1026-5
18.
LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-01995-0
19.
Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network.
Stem Cell Reports (2019). doi:10.1016/j.stemcr.2018.12.007
20.
Clustering of Tau fibrils impairs the synaptic composition of α3‐Na+/K+‐ATPase and AMPA receptors.
The EMBO Journal e99871 (2019). doi:10.15252/embj.201899871
21.
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
Journal of Neurochemistry 150, 522–534 (2019). doi:10.1111/jnc.14808
22.
How is alpha‐synuclein cleared from the cell?.
Journal of Neurochemistry 150, 577–590 (2019). doi:10.1111/jnc.14704
23.
Structures of filaments from Pick’s disease reveal a novel tau protein fold.
Nature 561, 137–140 (2018). doi:10.1038/s41586-018-0454-y
24.
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson’s disease cohort versus Parkinson’s disease: 123I-FP-CIT IMAGING IN A P.A53T PD COHORT.
Movement Disorders 33, 1734–1739 (2018). doi:10.1002/mds.27451
25.
Cryo-EM structures of tau filaments from Alzheimer’s disease.
Nature 547, 185–190 (2017). doi:10.1038/nature23002

1.
Distinct alpha‐Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH‐SY5Y cells.
Journal of Neurochemistry jnc.15174 (2020). doi:10.1111/jnc.15174
2.
Prominent microglial inclusions in transgenic mouse models of α-synucleinopathy that are distinct from neuronal lesions.
Acta Neuropathologica Communications 8, 133 (2020). doi:10.1186/s40478-020-00993-8
3.
The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies.
Acta Neuropathologica 139, 977–1000 (2020). doi:10.1007/s00401-020-02157-3
4.
Structures of α-synuclein filaments from multiple system atrophy.
Nature 1–6 (2020). doi:10.1038/s41586-020-2317-6
5.
Emergence of stealth polymorphs that escape α-synuclein amyloid monitoring, take over and acutely spread in neurons.
(Neuroscience, 2020). http://biorxiv.org/lookup/doi/10.1101/2020.02.11.943670.
6.
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
bioRxiv 2020.01.27.921643 (2020). doi:10.1101/2020.01.27.921643
7.
Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs.
Biophysical Journal (2020). doi:10.1016/j.bpj.2020.01.022
8.
The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding.
Scientific Reports 10, 4895 (2020). doi:10.1038/s41598-020-61757-x
9.
α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb.
Acta Neuropathologica Communications 7, 221 (2019). doi:10.1186/s40478-019-0859-3
10.
Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy.
eLife 8, e48907 (2019). doi:10.7554/eLife.48907
11.
Novel tau filament fold in corticobasal degeneration, a four-repeat tauopathy.
bioRxiv 811703 (2019). doi:10.1101/811703
12.
Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
Neurobiology of Disease 129, 38–43 (2019). doi:10.1016/j.nbd.2019.05.002
13.
The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.
Frontiers in Immunology 10, 1139 (2019). doi:10.3389/fimmu.2019.01139
14.
Pharmacological Transdifferentiation of Human Nasal Olfactory Stem Cells into Dopaminergic Neurons.
Stem Cells International 2019, 1–15 (2019). doi:10.1155/2019/2945435
15.
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved.
Frontiers in Molecular Neuroscience 12, 107 (2019). doi:10.3389/fnmol.2019.00107
16.
Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-02014-y
17.
Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules.
Nature 568, 420–423 (2019). doi:10.1038/s41586-019-1026-5
18.
LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-01995-0
19.
Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network.
Stem Cell Reports (2019). doi:10.1016/j.stemcr.2018.12.007
20.
Clustering of Tau fibrils impairs the synaptic composition of α3‐Na+/K+‐ATPase and AMPA receptors.
The EMBO Journal e99871 (2019). doi:10.15252/embj.201899871
21.
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
Journal of Neurochemistry 150, 522–534 (2019). doi:10.1111/jnc.14808
22.
How is alpha‐synuclein cleared from the cell?.
Journal of Neurochemistry 150, 577–590 (2019). doi:10.1111/jnc.14704
23.
Structures of filaments from Pick’s disease reveal a novel tau protein fold.
Nature 561, 137–140 (2018). doi:10.1038/s41586-018-0454-y
24.
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson’s disease cohort versus Parkinson’s disease: 123I-FP-CIT IMAGING IN A P.A53T PD COHORT.
Movement Disorders 33, 1734–1739 (2018). doi:10.1002/mds.27451
25.
Cryo-EM structures of tau filaments from Alzheimer’s disease.
Nature 547, 185–190 (2017). doi:10.1038/nature23002

1.
Distinct alpha‐Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH‐SY5Y cells.
Journal of Neurochemistry jnc.15174 (2020). doi:10.1111/jnc.15174
2.
Prominent microglial inclusions in transgenic mouse models of α-synucleinopathy that are distinct from neuronal lesions.
Acta Neuropathologica Communications 8, 133 (2020). doi:10.1186/s40478-020-00993-8
3.
The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies.
Acta Neuropathologica 139, 977–1000 (2020). doi:10.1007/s00401-020-02157-3
4.
Structures of α-synuclein filaments from multiple system atrophy.
Nature 1–6 (2020). doi:10.1038/s41586-020-2317-6
5.
Emergence of stealth polymorphs that escape α-synuclein amyloid monitoring, take over and acutely spread in neurons.
(Neuroscience, 2020). http://biorxiv.org/lookup/doi/10.1101/2020.02.11.943670.
6.
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
bioRxiv 2020.01.27.921643 (2020). doi:10.1101/2020.01.27.921643
7.
Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs.
Biophysical Journal (2020). doi:10.1016/j.bpj.2020.01.022
8.
The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding.
Scientific Reports 10, 4895 (2020). doi:10.1038/s41598-020-61757-x
9.
α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb.
Acta Neuropathologica Communications 7, 221 (2019). doi:10.1186/s40478-019-0859-3
10.
Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy.
eLife 8, e48907 (2019). doi:10.7554/eLife.48907
11.
Novel tau filament fold in corticobasal degeneration, a four-repeat tauopathy.
bioRxiv 811703 (2019). doi:10.1101/811703
12.
Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
Neurobiology of Disease 129, 38–43 (2019). doi:10.1016/j.nbd.2019.05.002
13.
The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.
Frontiers in Immunology 10, 1139 (2019). doi:10.3389/fimmu.2019.01139
14.
Pharmacological Transdifferentiation of Human Nasal Olfactory Stem Cells into Dopaminergic Neurons.
Stem Cells International 2019, 1–15 (2019). doi:10.1155/2019/2945435
15.
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved.
Frontiers in Molecular Neuroscience 12, 107 (2019). doi:10.3389/fnmol.2019.00107
16.
Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-02014-y
17.
Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules.
Nature 568, 420–423 (2019). doi:10.1038/s41586-019-1026-5
18.
LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-01995-0
19.
Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network.
Stem Cell Reports (2019). doi:10.1016/j.stemcr.2018.12.007
20.
Clustering of Tau fibrils impairs the synaptic composition of α3‐Na+/K+‐ATPase and AMPA receptors.
The EMBO Journal e99871 (2019). doi:10.15252/embj.201899871
21.
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
Journal of Neurochemistry 150, 522–534 (2019). doi:10.1111/jnc.14808
22.
How is alpha‐synuclein cleared from the cell?.
Journal of Neurochemistry 150, 577–590 (2019). doi:10.1111/jnc.14704
23.
Structures of filaments from Pick’s disease reveal a novel tau protein fold.
Nature 561, 137–140 (2018). doi:10.1038/s41586-018-0454-y
24.
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson’s disease cohort versus Parkinson’s disease: 123I-FP-CIT IMAGING IN A P.A53T PD COHORT.
Movement Disorders 33, 1734–1739 (2018). doi:10.1002/mds.27451
25.
Cryo-EM structures of tau filaments from Alzheimer’s disease.
Nature 547, 185–190 (2017). doi:10.1038/nature23002

1.
Distinct alpha‐Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH‐SY5Y cells.
Journal of Neurochemistry jnc.15174 (2020). doi:10.1111/jnc.15174
2.
Prominent microglial inclusions in transgenic mouse models of α-synucleinopathy that are distinct from neuronal lesions.
Acta Neuropathologica Communications 8, 133 (2020). doi:10.1186/s40478-020-00993-8
3.
The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies.
Acta Neuropathologica 139, 977–1000 (2020). doi:10.1007/s00401-020-02157-3
4.
Structures of α-synuclein filaments from multiple system atrophy.
Nature 1–6 (2020). doi:10.1038/s41586-020-2317-6
5.
Emergence of stealth polymorphs that escape α-synuclein amyloid monitoring, take over and acutely spread in neurons.
(Neuroscience, 2020). http://biorxiv.org/lookup/doi/10.1101/2020.02.11.943670.
6.
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
bioRxiv 2020.01.27.921643 (2020). doi:10.1101/2020.01.27.921643
7.
Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs.
Biophysical Journal (2020). doi:10.1016/j.bpj.2020.01.022
8.
The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding.
Scientific Reports 10, 4895 (2020). doi:10.1038/s41598-020-61757-x
9.
α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb.
Acta Neuropathologica Communications 7, 221 (2019). doi:10.1186/s40478-019-0859-3
10.
Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy.
eLife 8, e48907 (2019). doi:10.7554/eLife.48907
11.
Novel tau filament fold in corticobasal degeneration, a four-repeat tauopathy.
bioRxiv 811703 (2019). doi:10.1101/811703
12.
Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
Neurobiology of Disease 129, 38–43 (2019). doi:10.1016/j.nbd.2019.05.002
13.
The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.
Frontiers in Immunology 10, 1139 (2019). doi:10.3389/fimmu.2019.01139
14.
Pharmacological Transdifferentiation of Human Nasal Olfactory Stem Cells into Dopaminergic Neurons.
Stem Cells International 2019, 1–15 (2019). doi:10.1155/2019/2945435
15.
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved.
Frontiers in Molecular Neuroscience 12, 107 (2019). doi:10.3389/fnmol.2019.00107
16.
Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-02014-y
17.
Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules.
Nature 568, 420–423 (2019). doi:10.1038/s41586-019-1026-5
18.
LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-01995-0
19.
Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network.
Stem Cell Reports (2019). doi:10.1016/j.stemcr.2018.12.007
20.
Clustering of Tau fibrils impairs the synaptic composition of α3‐Na+/K+‐ATPase and AMPA receptors.
The EMBO Journal e99871 (2019). doi:10.15252/embj.201899871
21.
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
Journal of Neurochemistry 150, 522–534 (2019). doi:10.1111/jnc.14808
22.
How is alpha‐synuclein cleared from the cell?.
Journal of Neurochemistry 150, 577–590 (2019). doi:10.1111/jnc.14704
23.
Structures of filaments from Pick’s disease reveal a novel tau protein fold.
Nature 561, 137–140 (2018). doi:10.1038/s41586-018-0454-y
24.
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson’s disease cohort versus Parkinson’s disease: 123I-FP-CIT IMAGING IN A P.A53T PD COHORT.
Movement Disorders 33, 1734–1739 (2018). doi:10.1002/mds.27451
25.
Cryo-EM structures of tau filaments from Alzheimer’s disease.
Nature 547, 185–190 (2017). doi:10.1038/nature23002

Latest news

Erwan Bézard awarded one of the prestigious @ERC_Research Synergy Grants.

The laboratories of Erwan Bézard (Research Director INSERM; Institute of Neurodegenerative Disorders), Laurent Groc (Research Director CNRS ...

It’s #CRISPR.

Emmanuelle Charpentier and Jennifer Doudna ,who pioneered the revolutionary gene-editing technology, are the winners of this year’s ...

Joined publication in JNC by IMPRiND partners BRFAA and CNRS.

The collaboration within IMPRiND lead to a publication on Journal of Neurochemistry untitled " Distinct alpha‐Synuclein species induced ...

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.

© 2019 IMPRiND Project – created by SCIPROMPrivacy policy